Kardiale Fibrosen unter Dopaminagonisten - was gibt es Neues?
Kardiale Fibrosen unter Dopaminagonisten - was gibt es Neues?
A plain-language reading has not been prepared for this paper yet.
Original abstract
In order to avoid dyskinesias, de novo Parkinson patients are preferentially treated with dopamine agonists. Dopamine agonists can be classified into ergot- and non-ergot derivatives. Most recent investigations indicate that dopamine agonists of the ergot type carry an increased risk of restrictive valvular heart disease. This is particularly the case for pergolide and cabergoline. On average, about 18 % of individuals over the age of 50 with risk factors such as arterial hypertension, diabetes mellitus or nicotine abuse also present with a vavulopathy, whilst 25 % of patients treated with pergolide and cabergoline show such abnormalities. The clinical relevance of these restrictive heart valve abnormalities is limited, because only 1 % of all patients present with indicative clinical symptoms such as shortness of breath or edema. Nevertheless, pergolide and cabergoline have now been downgraded to second-line treatment of Parkinson's disease.